Blinding keeps knowledge of the assigned treatment from the people who could be biased by it. Doing it well means deciding who to mask, making treatments look alike, separating unblinded staff, planning emergency unblinding and checking afterwards. This guide covers each, including the data-system side that often leaks.
Free sandbox · No credit card · 21 CFR Part 11 aligned
| Participant | Treating clinician | Outcome assessor | |
|---|---|---|---|
| Open label | |||
| Single blind | |||
| Double blind | |||
| Triple blind (common usage) | |||
| Assessor-blinded (PROBE) |
Blinding in brief
Why blind
Knowledge of the assigned treatment changes behaviour. Participants who know they got the active drug may report symptoms differently or drop out less; clinicians may manage side effects, add concomitant medication or encourage adherence differently; assessors may score a borderline response more generously. These effects are largest for subjective outcomes such as pain, mood or global impression, and smaller for hard outcomes such as death. Blinding reduces performance bias and detection bias, and the reporting standard for randomised trials, CONSORT, asks authors to say who was blinded and how.
Blinding cannot be used everywhere. A surgical trial, an exercise program or a drug with an obvious side effect may not allow masking of participants or clinicians. In that case design for what you can mask, usually the outcome assessor and the statistician, and say so honestly. A blinded independent outcome review, objective endpoints and a pre-specified analysis plan then carry more of the load. See our guide to randomization software for the allocation side, which blinding depends on.
Choosing the design
In common usage, a single-blind study hides the assignment from the participant; a double-blind study hides it from the participant and from those administering or managing the intervention; and a triple-blind study also hides it from those evaluating outcomes, sometimes from the data monitoring committee or statistician as well. Sponsor SOPs define the tiers in slightly different ways, and journals have criticised the labels for being ambiguous, so state the roles.
Could this person's behaviour change the outcome if they knew? Could they learn the arm anyway (from side effects, taste, appearance, visit pattern)? Do they need to know for safety? If the answers say they need to know, keep them unblinded and make sure they are not also the assessor.
When participant or clinician blinding is impossible, a prospective randomised open-label blinded-endpoint (PROBE) design masks only the people judging outcomes. It is common in device, behavioural and procedural trials. The control is organisational: the assessor must not be in the room for treatment, must not see the chart pages that reveal the arm and must be asked not to discuss assignment with participants.
How to do it
Write each into the protocol, the pharmacy manual and the data management plan, so the plan does not live only in one person's head.
Use central or system-generated allocation so site staff cannot predict or alter the next assignment. See randomization list generator and EDC with randomization.
Use a placebo matched in appearance, taste, smell and packaging, with identical labelling apart from a coded kit or randomisation number. Where the active and control differ in route or schedule, use a double-dummy design: each participant gets one real and one placebo for each arm's regimen.
Pharmacy or an unblinded coordinator prepares and dispenses. The team that assesses, treats and enters outcomes stays blinded. Never let the same person do both. Record the roles in the delegation log.
Treatment arm, kit numbers, drug accountability and any unblinded lab results (for example drug levels) must not reach blinded users through forms, exports, reports or support tickets. Specify this in the data management plan, see data management plan template.
Define who can request and who can perform it, what justifies it (a safety need where knowing the arm changes management), how the participant continues in the study and how the event is recorded. Test the process before the first enrolment.
An independent data monitoring committee may see unblinded data for safety. Define who prepares those reports, how they are separated from the blinded team and when the study team learns the result.
Record every unplanned unblinding with who, when and why. Consider a short blinding questionnaire at the end of treatment. Report the method and any failures, as CONSORT asks.
In the free sandbox you can create a blinded role and an unblinded role, enter dummy participants and check what each role can see in forms, the AE page and exports. Do this before you write the final data management plan.
The data-system side
Most blinding breaks are data leaks, not guesses. In Capture, blinded roles never receive treatment-arm values; that is enforced with masked database views and row-level security, not only by hiding a field on the screen.
| Blinded coordinator | Unblinded administrator | |
|---|---|---|
| Treatment arm in casebook | Treatment assignment blinded | Visible |
| Drug accountability report | Blinded | Visible |
| Randomization list | ||
| Medication list |
Where blinding leaks
Walk through these with your data manager and pharmacist before launch.
Pilot the matching placebo with someone not in the study. Check packaging and labels too.
Consider an active placebo, and keep assessors away from adverse event detail that reveals the arm.
Use random kit numbers that do not reveal allocation order or blocks.
Blinded exports must omit them. Confirm with a test export in each role.
Keep unblinded safety reporting with a designated unblinded person or committee.
Route them to an unblinded user only, or mask them for the blinded team.
Use varying block sizes. See block randomization software.
Run a dry run, including the out-of-hours route, before the first participant.
Tell staff not to paste screenshots or arm information into tickets or messages.
Finish well
Routine unblinding happens after database lock, when the analysis plan says it may. Lock first, then unblind, and keep the sequence documented, see database lock. Retain the randomisation list, the unblinding log and any emergency unblinding records with the trial file.
In the report, describe who was blinded, how the interventions were made similar, how the code was held and any unblinding that occurred. This is also where your protocol language pays off: if the protocol stated roles, the report can be consistent. For wider design questions, the clinical trial protocol template has a placeholder for blinding and unmasking procedures. Regulators expect any premature unblinding to be explained, so keep contemporaneous notes and refer to ICH E6 and your sponsor SOPs for current wording.
Allocation concealment hides the upcoming assignment from those enrolling participants, before randomisation. Blinding hides the assignment from participants, clinicians or assessors after randomisation. Concealment prevents selection bias; blinding prevents performance and detection bias.
Single blind hides the assignment from the participant. Double blind also hides it from those administering or managing the intervention. Triple blind adds those evaluating outcomes, sometimes also the statistician or committee. Sponsors define the tiers differently, so list the roles in the protocol.
Use a double-dummy design: participants in each arm receive the active version of their own treatment and a placebo of the other, so everyone takes the same number of products on the same schedule.
When knowing the assigned treatment is needed to manage a participant's safety. The protocol should name who may unblind, how it is recorded and what happens to that participant's data. Test the process before enrolment and record every event.
It is harder. Someone unblinded must prepare or label the supply. Use pre-labelled coded kits from the manufacturer or an unblinded designee not involved in assessment, and record roles in the delegation log.
It should withhold arm information from blinded roles in every view and export, keep randomization and drug supply data with unblinded users, and log exports and allocation. In Capture, blinded roles never receive treatment-arm values, enforced by masked views and row-level security.
Log unplanned unblinding events and consider asking participants and assessors at the end of treatment which arm they think they were in. Report the results and any failures with the trial publication.
Keep exploring
Blinded and unblinded role management in EDC
How masking is enforced.
Clinical trial randomization software
Allocation and concealment.
Randomization list generator
Build a list.
Block randomization software
Block sizes and stratification.
EDC with randomization
One platform and one audit trail.
IRT / IWRS
Central randomisation systems.
Database lock
Lock before unblinding.
Data management plan template
Write the masking rules down.
Free sandbox with every feature. No credit card, and you pay only when you go live with real participants.